Brief: Aquestive Therapeutics Reports Positive Results From Latest Clinical Studies Evaluating Pharmacokinetic And Pharmacodynamic Performance Of Anaphylm ™ (Epinephrine) Sublingual Film And Provides Findings From Recent Auto-Injector Clinical Study
31/05/2023 13:12
May 31 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS REPORTS POSITIVE RESULTS FROM
LATEST
CLINICAL STUDIES EVALUATING PHARMACOKINETIC AND PHARMACODYNAMIC
PERFORMANCE OF ANAPHYLM ™ (EPINEPHRINE) SUBLINGUAL FILM AND
PROVIDES FINDINGS FROM RECENT AUTO-INJECTOR CLINICAL STUDY
* AQUESTIVE THERAPEUTICS INC - CONTINUES TO EXPECT TO SUBMIT
PROTOCOL FOR PIVOTAL STUDY TO FDA IN Q3 2023
* AQUESTIVE THERAPEUTICS - THERE WERE NO SIGNIFICANT ADVERSE
EVENTS REPORTED DURING STUDY, ANAPHYLM CONTINUES TO BE SAFE AND
WELL-TOLERATED BY SUBJECTS
Source text for Eikon: ID:nGNX5V2tth
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million